Sage Therapeutics Announced That Biogen Has Terminated Its Rights Under The Collaboration And License Agreement With Sage Specific To The SAGE-324 Program
Portfolio Pulse from Benzinga Newsdesk
Biogen has terminated its rights under the collaboration with Sage Therapeutics for the SAGE-324 program following negative Phase 2 study results. The companies have discontinued further development of SAGE-324 for essential tremor.
September 26, 2024 | 11:03 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biogen has terminated its collaboration with Sage Therapeutics on the SAGE-324 program due to negative Phase 2 results, impacting its pipeline for essential tremor treatment.
The termination of the collaboration and discontinuation of SAGE-324 development removes a potential product from Biogen's pipeline, likely leading to a negative short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Sage Therapeutics faces a setback as Biogen terminates its rights to the SAGE-324 program following negative trial results, halting development for essential tremor.
The discontinuation of SAGE-324 development is a significant setback for Sage Therapeutics, likely leading to a negative short-term impact on its stock price due to the loss of a potential treatment in its pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90